News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Epigenomics AG
23.09.2020 / 08:36
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Epigenomics AG
Geneststraße 5
10829 Berlin
Deutschland

Notification pursuant to Sec. 43 of the German Securities Trading Act

22nd September 2020

Dear Sirs,

Referring to the voting rights notification dated 16/09/2020 notifying that Morgan Stanley, Wilmington, Delaware, USA, has exceeded the threshold of 10% of the voting rights in Epigenomics AG, we hereby make the following notification pursuant to Sec. 43 of the German Securities Trading Act (Wertpapierhandelsgesetz):

1. The acquisition of voting rights resulting in Morgan Stanley exceeding the notification threshold of 10% of the voting rights in Epigenomics AG did not serve the purpose of strategic goals; rather it was made in the context of client facilitation.

2. Morgan Stanley may in the next 12 months acquire further voting rights in Epigenomics AG, in particular in the context of client facilitation.

3. Morgan Stanley does not intend to influence the composition of the management board, supervisory board or any other administrative body of Epigenomics AG.

4. Morgan Stanley does not intend to cause a significant change in the capital structure of Epigenomics AG, in particular not of the ratio between equity and debt financing and the dividend policy.

5. The acquisition of voting rights resulting in Morgan Stanley exceeding the notification threshold of 10% of the voting rights in Epigenomics AG resulted from and/or was made in the context of client facilitation. The acquisition was financed by a combination of external and Morgan Stanley own funds.


23.09.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this